<DOC>
	<DOC>NCT01183884</DOC>
	<brief_summary>The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.</brief_summary>
	<brief_title>3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Diagnosis of NB as defined by a) histopathology (confirmed by the MSKCC Department of Pathology), or b) BM metastases or MIBGavid lesion(s) plus high urine catecholamine levels. Highrisk NB as defined by riskrelated treatment guidelines1 and the International NB Staging System,89 i.e., stage 4 with (any age) or without (&gt; or = to 18 months of age) MYCN amplification, MYCNamplified stage 2 or stage 3 (any age), or MYCNamplified stage 4S. The patients are in &gt;2nd CR/VGPR, including no measurable MIBGavid soft tissue tumor assessable for response. Signed informed consent indicating awareness of the investigational nature of this program. Creatinine &gt; 3.0 mg/dL ALT, AST and Alkaline Phosphatase &gt; 5.0 times the upper limit of normal Bilirubin &gt; 3.0 mg/dL Patients with grade 3 or higher toxicities (using the CTCAE v34.0) related to cardiac, neurological, pulmonary or gastrointestinal function as determined by physical exam. Patients must have normal blood pressure for age. Progressive disease History of allergy to mouse proteins Active lifethreatening infection. Human antimouse antibody (HAMA) titer &gt;1000 Elisa units/ml. Inability to comply with protocol requirements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GM-CSF</keyword>
	<keyword>MAB 3F8</keyword>
	<keyword>RETINOIC ACID (CIS-9 &amp; 13)</keyword>
	<keyword>09-160</keyword>
</DOC>